Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity-Reference-Cited by-同舟云学术

Effector mechanisms of IgA antibodies against CD20 include recruitment of myeloid cells for antibody-dependent cell-mediated cytotoxicity and complement-dependent cytotoxicity

Published:2017-04-27 Issue:3 Volume:181 Page:413-417
ISSN:0007-1048
Container-title:British Journal of Haematology
language:en
Short-container-title:Br J Haematol

Author:

Lohse Stefan¹,Loew Sebastian¹,Kretschmer Anna¹^ORCID,Jansen J. H. Marco²,Meyer Saskia²,ten Broeke Toine²,Rösner Thies¹,Dechant Michael³,Derer Stefanie¹,Klausz Katja¹,Kellner Christian¹,Schwanbeck Ralf¹,French Ruth R.⁴,Tipton Thomas R. W.⁴,Cragg Mark S.⁴,Schewe Denis M.⁵,Peipp Matthias¹,Leusen Jeanette H. W.²,Valerius Thomas¹

Affiliation:

1. Division of Stem Cell Transplantation and Immunotherapy; Department of Internal Medicine II; Christian-Albrechts-University of Kiel; Kiel Germany

2. Laboratory of Translational Immunology; University Medical Centre Utrecht; Utrecht the Netherlands

3. Division of Nephrology; Department of Internal Medicine IV; Elblandklinikum Riesa; Riesa Germany

4. Antibody and Vaccine Group; Cancer Sciences Unit; Faculty of Medicine; Southampton University Hospitals; Southampton UK

5. Department of Paediatrics, Paediatric Haematology/Oncology; Christian-Albrechts-University of Kiel; Kiel Germany

Funder

Deutsche Forschungsgemeinschaft

Wilhelm Sander-Stiftung

Christian-Albrechts-Universität zu Kiel

Publisher

Wiley

Subject

Hematology

Link

http://onlinelibrary.wiley.com/wol1/doi/10.1111/bjh.14624/fullpdf

Reference10 articles.

1. Type II (tositumomab) anti-CD20 monoclonal antibody out performs type I (rituximab-like) reagents in B-cell depletion regardless of complement activation;Beers;Blood,2008

2. IgA EGFR antibodies mediate tumour killing in vivo;Boross;EMBO Molecular Medicine,2013

3. Type I CD20 antibodies recruit the B-cell receptor for complement-dependent lysis of malignant B cells;Engelberts;The Journal of Immunology,2016

4. Reformatting rituximab into human IgG2 and IgG4 isotypes dramatically improves apoptosis induction in vitro;Könitzer;PLoS ONE,2015

5. An anti-EGFR IgA that displays improved pharmacokinetics and myeloid effector cell engagement in vivo;Lohse;Cancer Research,2016

Cited by 28 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Engineering Dimeric EGFR-directed IgA Antibodies Reveals a Central Role of CD147 during Neutrophil-mediated Tumor Cell Killing of Head and Neck Squamous Cancer Cells;The Journal of Immunology;2024-05-24

2. Human IgG Fc-engineering for enhanced plasma half-life, mucosal distribution and killing of cancer cells and bacteria;Nature Communications;2024-03-07

3. Understanding Fc function for rational vaccine design against pathogens;mBio;2024-01-16

4. Fc receptors act as innate immune receptors during infection?;Frontiers in Immunology;2023-07-26

5. Antibody Fc-chimerism and effector functions: When IgG takes advantage of IgA;Frontiers in Immunology;2023-02-02